ReviewAdvances in pediatrics2026
The Hidden Burden: Endocrinopathies in Adolescents after Hematopoietic Stem Cell Transplantation.
Review in Advances in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Adolescents with malignant and nonmalignant diagnoses can require hematopoietic stem cell transplantation (HSCT), with the volume increasing 5% to 10% per annum in the United States. HSCT is an established therapy for malignancies, hemoglobinopathies, bone marrow failure, inborn errors of metabolism, and immunodeficiency. Gonadotoxic-conditioning regimens, immunosuppressive agents, and glucocorticoids are essential therapies required for a successful transplant course. Secondary endocrine sequelae can occur, however, including iatrogenic adrenal insufficiency, reduced bone mineral density, medication-induced hyperglycemia, and premature ovarian insufficiency. With broader indications for HSCT use, at-risk endocrinopathies in the post-transplant period require prompt recognition and assessment, monitoring, and medical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.